Российский междисциплинарный консенсус по определению «Сложный для ведения» и «Трудный для лечения» псориатический артрит / псориаз и ведению этих пациентов. Положения дерматовенерологов

Псориаз оказывает выраженное негативное воздействие на качество жизни пациентов, включая социальную стигматизацию, а также связан с различными коморбидными патологиями, в том числе психосоциальными проблемами. Несмотря на множество научных исследований, различных подходов ведения пациентов, наличие современных препаратов, все еще остается ряд проблем и задач, которые стоят перед медицинским сообществом, включая вопросы стратификации категорий пациентов, представляющих сложности в их ведения. В статье представлены результаты консенсуса российских экспертов по формированию определений «Сложный для ведения» и «Трудный для лечения» пациент при псориазе и ведению этих больных.

1. van Ee I, Deprez E, Egeberg A, et al. Freedom from disease in psoriasis: a Delphi consensus definition by patients, nurses and physicians. J Eur Acad Dermatol Venereol. 2022; 36 (3): 403–412. DOI: 10.1111/jdv.17829

2. Zusman EZ, Howren AM, Park JYE, Dutz J, De Vera MA. Epidemiology of depression and anxiety in patients with psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020; 50 (6). DOI: 10.1016/j.semarthrit.2020.02.001] [Zhao SS, Miller N, Harrison N, Duffield SJ, Dey M, Goodson NJ. Systematic review of mental health comorbidities in psoriatic arthritis. Clin Rheumatol. 2020; 39 (1): 217–225. DOI: 10.1007/s10067-019-04734-8

3. Coates LC, Orbai A-M, Azevedo VF, et al. Results of a global, patient-based survey assessing the impact of psoriatic arthritis discussed in the context of the psoriatic arthritis impact of disease (PsAID) questionnaire. Health Qual Life Outcomes 2020; 18: 173. 10.1186/s12955-020-01422-z

4. Scala E, Mercurio L, Albanesi C, Madonna S. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity. Life (Basel). 2024; 14 (6): 733. Published 2024 Jun 7. DOI: 10.3390/life14060733

5. Lubrano E, Scriffignano S, Azuaga AB. Impact of comorbidities on disease activity, patient global assessment and function in Psoriatic Arthritis: A Cross-Sectional Study. Rheumatol Ther. 2020; 7: 825–836. DOI: 10.1007/s40744-020-00229-0

6. Переверзина Н.О., Круглова Л.С., Коротаева Т.В., Руднева Н.С. Раннее назначение генно-инженерных биологических препаратов как эффективная вторичная профилактика псориатического артрита. Медицинский алфавит. 2025; (23): 33–38. https://doi.org/10.33667/2078-5631-2025-23-33-38

7. Ribeiro AL, Singla S, Chandran V, et al. Deciphering difficult-to-treat psoriatic arthritis (D2T-PsA): a GRAPPA perspective from an international survey of healthcare professionals. Rheumatol Adv Pract. 2024; 8 (3): rkae074. Published 2024 Jun 19. DOI: 10.1093/rap/rkae074

8. Singla S, Ribeiro A, Torgutalp M, Mease PJ, Proft F. Difficult-to-treat psoriatic arthritis (D2T PsA): a scoping literature review informing a GRAPPA research project. RMD Open. 2024; 10 (1): e003809. Published 2024 Jan 8. doi: 10.1136/rmdopen-2023–003809

9. Nagy G, Roodenrijs NMT, Welsing PMJ, et al. EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2022; 81 (1): 20–33. DOI: 10.1136/annrheumdis-2021-220973

10. Sewerin P, Borchert K, Meise D, et al. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis – a retrospective database study. Rheumatol Ther. 2021; 8: 483–497. DOI: 10.1007/s40744-021-00286-z

11. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020; 79: 700–712. DOI: 10.1136/annrheumdis-2020–2171159

12. Glintborg B, Di Giuseppe D, Wallman JK, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis.2023; 82: 820–828. DOI: 10.1136/ard-2022–223650

13. Nicolescu A.C. et al. Psoriasis management challenges regarding difficult-to-treat areas: therapeutic decision and effectiveness // Life. 2022. Т. 12. № . 12. С. 2050.

14. Sarma N. Evidence and suggested therapeutic approach in psoriasis of difficult-to-treat areas: palmoplantar psoriasis, nail psoriasis, scalp psoriasis, and intertriginous psoriasis // Indian Journal of Dermatology. 2017. Т. 62. № . 2. С. 113–122.

15. Mastorino L. et al. Patients with psoriasis resistant to multiple biological therapies: characteristics and definition of a difficult-to-treat population // British Journal of Dermatology. 2022. Т. 187. № . 2. С. 263–265

16. Magnano M. et al. Secukinumab in multi-failure psoriatic patients: the last hope? // Journal of Dermatological Treatment. 2018. Т. 29. № . 6. С. 583–585.

17. Megna M, Fabbrocini G, Ruggiero A, Cinelli E. Efficacy and safety of risankizumab in psoriasis patients who failed anti-IL-17, anti-12/23 and/or anti IL-23: preliminary data of a real-life 16- week retrospective study. Dermatol Ther 2020; 33: e14144.

18. Bonifati C, Morrone A, Cristaudo A, Graceffa D. Effectiveness of anti-interleukin 23 biologic drugs in psoriasis patients who failed anti-interleukin 17 regimens. A real-life experience. Dermatol Ther 2021; 34: e14584.

19. Lorenzin M, Ortolan A, Cozzi G et al. Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNFα, anti-IL12/23, or anti-IL17 drugs: a 15-year monocentric real-life study. Clin Rheumatol 2021; 40: 4569–80.

20. Nast A, Smith C, Spuls PI et al. EuroGuiDerm Guideline on the systemic treatment of psoriasis vulgaris – part 2: specific clinical and comorbid situations. J Eur Acad Dermatol Venereol 2021; 35: 281–317.

21. Radtke M.A., Reich K., Spehr C., Augustin M. Treatment goals in psoriasis routine care. Arch Dermatol Res. 2015 Jul; 307 (5): 445–9.

22. Круглова, Л.С. Новый подход к ведению пациентов с псориазом кожи и аксиальными поражениями: ранняя диагностика и ускоренная терапия / Л.С. Круглова, Н.О. Переверзина, Н.С. Руднева // Эффективная фармакотерапия. 2023. Т. 19, № 19. С. 6–14. DOI 10.33978/2307-3586-2023-19-19-6-14

23. Strober B.E., Clay Cather J., Cohen D., Crowley J.J., Gordon K.B., Gottlieb A.B., Kavanaugh A.F., Korman N.J., Krueger G.G., Leonardi C.L. et al. A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb). 2012 Dec; 2 (1):1. Epub 2012 Mar 17.

24. Strober B.E., Clay Cather J., Cohen D., Crowley J.J., Gordon K.B., Gottlieb A.B., Kavanaugh A.F., Korman N.J., Krueger G.G., Leonardi C.L. et al A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part. 2. Dermatol Ther (Heidelb). 2012 Dec; 2 (1): 2. Epub 2012 Mar 30]

25. Schett G, Rahman P, Ritchlin C, et al. Psoriatic arthritis from a mechanistic perspective. Nat Rev Rheumatol. 2022; 18 (6):311–325. DOI: 10.1038/s41584–022–00776–6

26. Becher Strand et al/ Immunogenicity of biologics in chronic inflammatory diseases. A systematic review. BioDrugs 2017; 31 (4): 299–316.

27. Bakulev A.L. The actual challenges of biologics treatment in patients with psoriasis // Vestnik dermatologii i venerologii. 2020. Т. 96. № . 2. С. 51–57.

28. Augustin M., Thaci D., Eyerich K., Pinter A., Radtke M., Lauffer F., Mrowietz U., Gerdes S., Pariser D., Lebwohl M., Sieder C., Melzer N., Reich K. Continued treatment with secukinumab is associated with high retention

29. Shahwan KT, Kimball AB. Managing the dose escalation of biologics in an era of cost containment: the need for a rational strategy. Int J Womens Dermatol. 2016 Oct 26; 2 (4): 151–153. DOI: 10.1016/j.ijwd.2016.09.003. PMID: 28492030; PMCID: PMC5419024.

30. Li W, Han J, Qureshi AA. Obesity and risk of incident psoriatic arthritis in US women. Ann Rheum Dis. 2012; 71 (8): 1267–1272. DOI: 10.1136/annrheumdis-2011–201273.

31. Scala E, Mercurio L, Albanesi C, Madonna S. The Intersection of the Pathogenic Processes Underlying Psoriasis and the Comorbid Condition of Obesity. Life (Basel). 2024; 14 (6): 733. DOI: 10.3390/life14060733

32. Chiricozzi A, Gisondi P, Girolomoni G. The pharmacological management of patients with comorbid psoriasis and obesity. Expert Opin Pharmacother. 2019; 20 (7): 863–872. DOI: 10.1080/14656566.2019.1583207

33. Currado D, Trunfio F, Saracino F, et al. Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients. RMD Open. 2025; 11 (2): e005717. DOI: 10.1136/rmdopen-2025–005717

34. Patsalos O, Dalton B, Leppanen J, Ibrahim MAA, Himmerich H. Impact of TNF-α Inhibitors on Body Weight and BMI: A Systematic Review and Meta-Analysis. Front Pharmacol. 2020; 11: 481. Published 2020 Apr 15. DOI: 10.3389/fphar.2020.00481

35. Gialouri CG, Evangelatos G, Fragoulis GE. Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?. Mediterr J Rheumatol. 2022; 33 (Suppl 1): 150–161. Published 2022 Apr 15. DOI: 10.31138/mjr.33.1.150

36. Siebert S, Sattar N, Ferguson LD. Weighing in on obesity and psoriatic arthritis – Time to move beyond association to robust randomised trials. Joint Bone Spine. 2025; 92 (5): 105904. DOI: 10.1016/j.jbspin.2025.105904

37. Carter K, Cheung WY, Hutchings HA, et al. The efficacy and safety of ustekinumab in adolescents newly diagnosed with type 1 diabetes: the USTEK1D RCT. Southampton (UK): National Institute for Health and Care Research; February 2025

38. da Silva BS, Bonfá E, de Moraes JC, et al. Effects of anti-TNF therapy on glucose metabolism in patients with ankylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologicals. 2010; 38 (5): 567–569. DOI: 10.1016/j.biologicals.2010.05.003

39. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011; 305 (24): 2525–2531. DOI: 10.1001/jama.2011.878

40. Puig L, Korman N, Greggio C, Cirulli J, Teng L, Chandran V, et al. Long-term hemoglobin A1c changes with apremilast in patients with psoriasis and psoriatic arthritis: pooled analysis of phase 3 ESTEEM and PALACE trials and phase 3b LIBERATE trial. J Am Acad Dermatol. 2019; 81: 89. DOI: 10.1016/j.jaad.2019.06.346

41. Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014;30(2):96–102. DOI: 10.1002/dmrr.2486

42. Katsuyama T, Sada KE, Namba S, et al. Risk factors for the development of glucocorticoid-induced diabetes mellitus. Diabetes Res Clin Pract. 2015; 108 (2): 273–279. DOI: 10.1016/j.diabres.2015.02.010

43. Di Minno MN, Peluso R, Iervolino S, et al. Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers. Ann Rheum Dis. 2014; 73 (6): 1157–1162. DOI: 10.1136/annrheumdis-2012–202812

44. Klingberg E, Bilberg A, Björkman S, et al. Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study. Arthritis Res Ther. 2019; 21 (1): 17. DOI: 10.1186/s13075-019-1810-5

45. Nicolau J, Nadal A, Sanchís P, Pujol A, Nadal C, Masmiquel L. Effects of liraglutide among patients living with psoriasis and obesity. Med Clin (Barc). 2023; 161 (7): 293–296. DOI: 10.1016/j.medcli.2023.05.021

46. Коротаева Т.В., Трошина Е.А., Лила А.М., Паневин Т.С., Насонов Е.Л., Корсакова Ю.Л., Глухова С.И. Эффективность лираглутида в комплексной терапии больных псориазом в сочетании с метаболическими нарушениями: метаанализ наблюдательных и контролируемых исследований. Ожирение и метаболизм. 2025; 22 (2): 70–76.

47. Maglio C, Peltonen M, Rudin A, Carlsson LMS. Bariatric surgery and the incidence of psoriasis and psoriatic arthritis in the Swedish obese subjects study. Obesity (Silver Spring). 2017; 25 (12): 2068–2073. DOI: 10.1002/oby.21955

48. Egeberg A, Sørensen JA, Gislason GH, et al. Incidence and prognosis of psoriasis and psoriatic arthritis in patients undergoing bariatric surgery [published correction appears in JAMA Surg. 2018; 153 (7): 692]. JAMA Surg. 2017;152(4):344–349. DOI: 10.1001/jamasurg.2016.4610

49. Goel N, Wallace EB, Lindsay C. Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis. J Rheumatol. October 2024: jrheum. 2024–0362. DOI: 10.3899/jrheum.2024–0362

50. Bell KA, Balogh EA, Feldman SR. An update on the impact of depression on the treatment of psoriasis. Expert Opin Pharmacother. 2021; 22 (6). DOI: 10.1080/14656566.2020.1849141

51. Wang X, Wu L, Liu J, Ma C, Liu J, Zhang Q. The neuroimmune mechanism of pain induced depression in psoriatic arthritis and future directions. Biomedicine and Pharmacotherapy. 2025; 182. DOI: 10.1016/j.biopha.2024.117802

52. Mathew AJ, Chandran V. Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation. Rheumatol Ther. 2020; 7 (2). DOI: 10.1007/s40744-020-00207-6

53. Goel N, Wallace EB, Lindsay C. Hot Topics: Depression in Individuals With Psoriasis and Psoriatic Arthritis. J Rheumatol. October 2024: jrheum. 2024–0362. DOI: 10.3899/jrheum.2024–0362

54. Wang M, Sun Y, Sun Y. Efficacy and safety of drugs for psoriasis patients with mental disorders: A systematic review. J Affect Disord. 2024; 365: 112–125. DOI: 10.1016/j.jad.2024.08.077

55. Sood A, Raji MA. Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs. Clin Rheumatol. 2021; 40 (4). DOI: 10.1007/s10067-020-05372-1

56. Reich K, Foley P, Han C, et al. Guselkumab improves work productivity in patients with moderate-to-severe psoriasis with or without depression and anxiety: results from the VOYAGE2 comparator study versus adalimumab. J Dermatolog Treat. 2020; 31 (6): 617–623. DOI: 10.1080/09546634.2019.1628172

57. Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022; 386 (4): 316–326. DOI: 10.1056/NEJMoa2109927

58. Curtis JR, Yamaoka K, Chen YH, et al. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023; 82 (3): 331–343. DOI: 10.1136/ard-2022–222543

59. Raaschou P, Simard JF, Holmqvist M, Askling J; ARTIS Study Group. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma: nationwide population based prospective cohort study from Sweden. BMJ. 2013; 346: f1939. DOI: 10.1136/bmj.f1939

60. Raaschou P, Frisell T, Askling J; ARTIS Study Group. TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis. 2015; 74 (12): 2137–2143. DOI: 10.1136/annrheumdis-2014–205745

61. Phillips C, Zeringue AL, McDonald JR, Eisen SA, Ranganathan P. Tumor Necrosis Factor Inhibition and Head and Neck Cancer Recurrence and Death in Rheumatoid Arthritis. PLoS One. 2015; 10 (11): e0143286. Published 2015 Nov 23. DOI: 10.1371/journal.pone.0143286

62. Sebbag E, Lauper K, Molina-Collada J, et al. 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer. Ann Rheum Dis. Published online December 20, 2024. DOI: 10.1136/ard-2024–225982

63. Avouac J, Ait-Oufella H, Habauzit C, Benkhalifa S, Combe B. The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations. Rheumatol Ther. 2025; 12 (2): 211–236. DOI: 10.1007/s40744–025–00753-x

64. Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023; 37 (1): 35–55. DOI: 10.1007/s40259–022–00569-z

65. Poizeau F, Nowak E, Kerbrat S, et al. Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. JAMA Dermatol. 2020; 156 (11): 1208–1215. DOI: 10.1001/jamadermatol.2020.2977

66. Kimball AB, Papp KA, Wasfi Y, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013; 27 (12): 1535–1545. DOI: 10.1111/jdv.12046

67. Nakamura M, Abrouk M, Farahnik B, Zhu TH, Bhutani T. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018; 101 (1): 38;42;56.

68. Pangilinan MCG, Sermswan P, Asawanonda P. Use of anti-IL-17 monoclonal antibodies in HIV patients with Erythrodermic Psoriasis. Case Rep Dermatol. 2020; 12 (2): 132–7.

69. Di Lernia V, Casanova DM, Garlassi E. Secukinumab in an HIV-positive patient with psoriasis. J Dtsch Dermatol Ges. 2019; 17 (6): 646–8.

70. Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018; 24 (11): 13030.

71. Myers B, Thibodeaux Q, Reddy V, et al. Biologic Treatment of 4 HIV-Positive Patients: A Case Series and Literature Review. J Psoriasis Psoriatic Arthritis. 2021; 6 (1): 19–26. DOI: 10.1177/2475530320954279

72. Saeki H, Ito T, Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol. 2015;29(8):1653–1655. doi:10.1111/jdv.12531.

73. Qian F, Yan Y, Huang J, et al. Use of ixekizumab in an HIV-positive patient with psoriatic arthritis. Int J STD AIDS. 2022; 33 (5): 519–521. DOI: 10.1177/09564624221076289

74. Orsini D, Maramao FS, Gargiulo L, et al. Effectiveness and safety of risankizumab in HIV patients with psoriasis: A case series. Int J STD AIDS. 2024; 35 (1): 67–70. DOI: 10.1177/09564624231199510

75. Bonifati C, Lora V, Graceffa D, Nosotti L. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016; 22 (28): 6444–55.

76. Piaserico S, Messina F, Russo FP. Managing Psoriasis in Patients with HBV or HCV Infection: Prac‑ tical Considerations. Am J Clin Dermatol. 2019; 20 (6): 829–845. DOI: 10.1007/s40257‑019‑00457‑3

77. Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate‑to‑se‑ vere plaque psoriasis. J Eur Acad Dermatol Venereol. 2017; 31 (5): 774–790. DOI: 10.1111/jdv.14114

78. Cannizzaro MV, Franceschini C, Esposito M, Bianchi L, Giunta A. Hepatitis B reactivation in psoriasis patients treated with anti‑TNF agents: prevention and management. Psoriasis (Auckl). 2017; 7: 35–40. Published 2017 Apr 15. DOI: 10.2147/PTT.S108209

79. Koskinas J, Tampaki M, Doumba PP, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a hepatitis B surface‑antigen‑negative anti‑HBs‑positive patient. Br J Dermatol. 2013; 168 (3): 679–680. DOI: 10.1111/bjd.12120

80. Crowley J, Thaçi D, Joly P, et al. Long‑term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol. 2017; 77 (2): 310–317.e1. DOI: 10.1016/j.jaad.2017.01.052

81. Crowley JJ, Warren RB, Cather JC. Safety of selective IL‑23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019; 33 (9): 1676–1684. DOI: 10.1111/jdv.15653]

82. Torres T, Chiricozzi A, Puig L, et al. Treatment of Psoriasis Patients with Latent Tuberculosis Using IL‑17 and IL‑23 Inhibitors: A Retrospective, Multinational, Multicentre Study. Am J Clin Dermatol. 2024; 25 (2): 333–342. DOI: 10.1007/s40257–024–00845–4

83. Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta‑analysis of randomised controlled trials. BMJ Open. 2017; 7 (3): e012567. DOI: 10.1136/bmjopen‑2016–012567

84. Cantini F, Nannini C, Niccoli L, et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev. 2015; 14 (6): 503–509. DOI: 10.1016/j.autrev.2015.01.011